Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

This is a Phase II treatment, non-randomized, open label clinical trial to study the efficacy of the Cetuximab when administered as single agent in recurrent/ metastatic head and neck squamous cell carcinoma after the failure or intolerance of immuno-oncology or immuno-oncology combined with chemotherapy.

Trial Details

NCT ID
NCT04375384
Phase
PHASE2
Sponsor
Wake Forest University Health Sciences
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Cetuximab
  • Questionnaire administration
  • Quality of life assessment
Locations (sample)
  • Winston-Salem, North Carolina, United States|36.09986,-80.24422

Key Eligibility Criteria

  • Patients must have histologically or cytologically confirmed head and neck squamous cell carcinoma.
  • Measurable disease by scans- at least one measurable lesion.
  • Patients must have received previous treatment with immunotherapy with PD-1 inhibitor alone or in combination with chemotherapy.
  • Patients must have a Performance Status of 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →